Federated cloud-based Artificial Intelligence-driven platform for liquid biopsy analyses
From 01-02-2021 to 31-01-2023
Description
“Liquid biopsy” represents an emerging minimally invasive screening tool that can potentially allow monitoring tissue dynamics in multiple human physiological and pathological conditions. In turn, the current extensive analysis of various liquid biopsy biomarkers associated with big data generation paves the way towards data-driven precision medicine by enabling patient-oriented proactive, predictive, preventive and participatory health management. We have recently developed an innovative massive parallel sequencing-based approach for genome-wide cell-free DNA (cfDNA) profiling and combined it with novel data mining approaches (patent pending), enabling sensitive detection of pre-symptomatic cancer, autoimmune disorders, pregnancy complications, and other pathologies. Multiple genetic centers and genetic testing sites worldwide reached out to us willing to improve their diagnostic potential by applying our analytical pipeline. However, to properly address these demands, an efficient and rapid end-user friendly platform including our analytical pipeline and processing data in a federated way is lacking. As such, the goal of this project is to tackle the main challenges for productization in order to create scalable federated liquid biopsy platform: (1) Creation of a scalable cloud environment enabling fast and efficient sample classification; (2) Establishment of a software suite for analysis, visualization of cfDNA profiles and reporting of clinically-relevant findings; (3) Expansion of the cloud-based platform to allow data analysis and reporting to distributed sites; (4) Aggregation of large datasets from distributed sites. The creation of a performant federated data analytics platform will pave the road for a successful spin-off creation.
Team
- Yves Moreau, Co-promoter
Financing
Funding: KU Leuven - Internal Funding KU Leuven
Program/Grant Type: C3 - KU Leuven Category 3 Funding
Events
2/09/2024:
PhD defense - Martijn Oldenhof
Machine Learning for Advanced Chemical Analysis and Structure Recognition in Drug Discovery
3/09/2024:
Meet the Jury Igor Tetko on Advanced Machine Learning in Drug Discovery
12/09/2024:
Multimodal analysis of cell-free DNA for sensitive cancer detection in low-coverage and low-sample settings
Seminar by Antoine Passemiers
News
STADIUS Alumni Herman Verrelst – new CEO of Biocartis
08 June 2017
Herman Verrelst, the founder of KU Leuven spin-off Cartagenia, who has been working in Silicon Valley, US for the last few years will be returning to Belgium to follow the steps of Rudi Pauwels as CEO of the Belgian diagnostic company, Biocartis.
Supporting healthcare policymaking via machine learning – batteries included!
29 May 2017
STADIUS takes the lead in the data analytics efforts in an ambitious European Project MIDAS.
Marc Claesen gives an interview about his PhD for the magazine of the Faculty of Engineering Sciences "Geniaal"
10 February 2017
Did you know that in Belgium approximately one third of type 2 diabetes patients are unaware of their condition?
Joos Vandewalle is nieuwe voorzitter KVAB
09 October 2016
Op 5 oktober 2016 heeft de Algemene Vergadering van de Academie KVAB Joos Vandewalle verkozen tot voorzitter van de KVAB.